<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02651727</url>
  </required_header>
  <id_info>
    <org_study_id>VS-4718-103</org_study_id>
    <nct_id>NCT02651727</nct_id>
  </id_info>
  <brief_title>Ph 1 Study of VS-4718, a FAK Inhibitor, in Combination With Nab-paclitaxel and Gemcitabine in Advanced Cancer Subjects</brief_title>
  <official_title>A Phase 1 Study of VS-4718, a Focal Adhesion Kinase Inhibitor, in Combination With Nab-paclitaxel and Gemcitabine in Subjects With Advanced Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Verastem, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Verastem, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate increasing dose levels of VS-4718 administered in&#xD;
      combination with gemcitabine and nab-paclitaxel in subjects with advanced cancer and to&#xD;
      determine a recommended Phase 2 dose (RP2D) for further development of this combination in&#xD;
      subjects with untreated advanced pancreatic cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is comprised of 2 sequential parts: Part A (Dose Escalation of VS-4718) in subjects&#xD;
      with advanced cancer and Part B (Expansion) in subjects with untreated advanced pancreatic&#xD;
      cancer.&#xD;
&#xD;
      Up to 60 evaluable subjects (i.e., subjects who complete at least 1 cycle (28 days) of&#xD;
      therapy) will be enrolled, assuming that:&#xD;
&#xD;
        1. Part A: The maximum sample size will be 6 subjects up to 4 dose levels (exclusive of&#xD;
           replacement subjects). However, additional subjects may be added if exploration of&#xD;
           intermediate dose level(s) of VS 4718 is warranted. The starting dose of VS-4718 will be&#xD;
           200mg BID.&#xD;
&#xD;
        2. Part B: Up to 36 additional subjects may be enrolled at the RP2D. These subjects will be&#xD;
           randomized at a 1:1 ratio to 1 of 2 treatment cohorts:&#xD;
&#xD;
             -  Cohort 1: IV treatment in 28-day cycles (nab-paclitaxel 125 mg/m2 over 30 minutes&#xD;
                on Days 1, 8, and 15 and gemcitabine at 1000 mg/m2 over 30 minutes on Days 1, 8,&#xD;
                and 15) and oral VS 4718 BID continuously starting on Day 1 of Cycle 1&#xD;
&#xD;
             -  Cohort 2: IV treatment for the first 2 cycles, followed by IV treatment and oral&#xD;
                VS-4718 BID continuously starting on Day 1 of Cycle 3&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    the company's decision to de-prioritize 4718 development&#xD;
  </why_stopped>
  <start_date>September 2015</start_date>
  <completion_date type="Actual">January 2017</completion_date>
  <primary_completion_date type="Actual">January 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of dose-limiting toxicities (DLTs)</measure>
    <time_frame>6 months</time_frame>
    <description>Dose Escalation Phase: Frequency of DLTs at each dose level associated with administration of VS-4718 in combination with gemcitabine and nab-paclitaxel</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>From the date of first treatment to the date of progression including death from any cause, expected average at least 5 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response rate (RR)</measure>
    <time_frame>Every 8 weeks from baseline through the end of treatment, an expected average of 5 months]</time_frame>
    <description>RR is measured as the best overall response using Response Evaluation Criteria In Solid Tumors (RECIST), version 1.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of VS-4718 in combination with nab-paclitaxel and gemcitabine: Clearance</measure>
    <time_frame>Time points on Day 1, 2,15, 16, and 22 in Cycle 1; Day 1 of each subsequent cycle</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of VS-4718 in combination with nab-paclitaxel and gemcitabine: Plasma concentration</measure>
    <time_frame>Time points on Day 1, 2,15, 16, and 22 in Cycle 1; Day 1 of each subsequent cycle</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of VS-4718 in combination with nab-paclitaxel and gemcitabine: Area under the plasma concentration versus time curve (AUC)</measure>
    <time_frame>Time points on Day 1, 2,15, 16, and 22 in Cycle 1; Day 1 of each subsequent cycle</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of VS-4718 in combination with nab-paclitaxel and gemcitabine: Maximum observed plasma concentration (Cmax)</measure>
    <time_frame>Time points on Day 1, 2,15, 16, and 22 in Cycle 1; Day 1 of each subsequent cycle</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of VS-4718 in combination with nab-paclitaxel and gemcitabine: Time to reach maximum observed concentration (Tmax)</measure>
    <time_frame>Time points on Day 1, 2,15, 16, and 22 in Cycle 1; Day 1 of each subsequent cycle</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of VS-4718 in combination with nab-paclitaxel and gemcitabine: Half life (T1/2)</measure>
    <time_frame>Time points on Day 1, 2,15, 16, and 22 in Cycle 1; Day 1 of each subsequent cycle</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">13</enrollment>
  <condition>Pancreatic Cancer</condition>
  <arm_group>
    <arm_group_label>Part B, Cohort 1- VS-4718, nab-paclitaxel, gemcitabine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part B, Cohort 1- IV treatment in 28-day cycles (nab-paclitaxel 125 mg/m2 over 30 minutes on Days 1, 8, and 15 and gemcitabine at 1000 mg/m2 over 30 minutes on Days 1, 8, and 15) and oral VS 4718 BID continuously starting on Day 1 of Cycle 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B, Cohort 2- VS-4718, nab-paclitaxel, gemcitabine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part B, Cohort 2- IV treatment for the first 2 cycles (nab-paclitaxel 125 mg/m2 over 30 minutes on Days 1, 8, and 15 and gemcitabine at 1000 mg/m2 over 30 minutes on Days 1, 8, and 15), followed by IV treatment and oral VS-4718 BID continuously starting on Day 1 of Cycle 3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A- VS-4718, nab-paclitaxel, gemcitabine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part A- intravenous (IV) treatment in 28-day cycles (nab-paclitaxel 125 mg/m2 over 30 minutes on Days 1, 8, and 15 and gemcitabine at 1000 mg/m2 over 30 minutes on Days 1, 8, and 15) and oral VS 4718 twice-daily (BID) continuously starting on Cycle 1 Day 2. The starting dose of VS-4718 will be 200 mg BID.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Part B, Cohort 1- VS-4718, nab-paclitaxel, gemcitabine</intervention_name>
    <description>IV treatment in 28-day cycles (nab-paclitaxel 125 mg/m2 over 30 minutes on Days 1, 8, and 15 and gemcitabine at 1000 mg/m2 over 30 minutes on Days 1, 8, and 15) and oral VS 4718 BID continuously starting on Day 1 of Cycle 1</description>
    <arm_group_label>Part B, Cohort 1- VS-4718, nab-paclitaxel, gemcitabine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Part B, Cohort 2- VS4718, nab-paclitaxel, gemcitabine</intervention_name>
    <description>IV treatment for the first 2 cycles, followed by IV treatment and oral VS-4718 BID continuously starting on Day 1 of Cycle 3</description>
    <arm_group_label>Part B, Cohort 2- VS-4718, nab-paclitaxel, gemcitabine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Part A- VS-4718, nab-paclitaxel, gemcitabine</intervention_name>
    <description>Part A- intravenous (IV) treatment in 28-day cycles (nab-paclitaxel 125 mg/m2 over 30 minutes on Days 1, 8, and 15 and gemcitabine at 1000 mg/m2 over 30 minutes on Days 1, 8, and 15) and oral VS 4718 twice-daily (BID) continuously starting on Cycle 1 Day 2. The starting dose of VS-4718 will be 200 mg BID.</description>
    <arm_group_label>Part A- VS-4718, nab-paclitaxel, gemcitabine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥ 18 years&#xD;
&#xD;
          -  Histologically or cytologically confirmed diagnosis of an advanced nonhematological&#xD;
             malignancy (Part A) or advanced pancreatic adenocarcinoma (Part B) that is not&#xD;
             surgically resectable&#xD;
&#xD;
          -  Eligible for treatment with nab-paclitaxel and gemcitabine on Days 1, 8, and 15 in&#xD;
             28-day cycles as standard therapy&#xD;
&#xD;
          -  Evaluable or measurable disease, as assessed by RECIST v1.1&#xD;
&#xD;
          -  ECOG performance status of ≤ 1&#xD;
&#xD;
          -  Adequate renal function (creatinine ≤ 1.5×ULN [upper limit of normal]) or glomerular&#xD;
             filtration rate of ≥ 60 mL/min&#xD;
&#xD;
          -  Adequate hepatic function (total bilirubin ≤ 1.5×ULN for the institution; aspartate&#xD;
             transaminase and alanine transaminase ≤ 2.5×ULN, or ≤ 5×ULN if due to liver&#xD;
             involvement by tumor; albumin ≥ 3 g/dL)&#xD;
&#xD;
          -  Adequate bone marrow function (hemoglobin ≥ 9.0 g/dL; unsupported platelets ≥ 100×109&#xD;
             cells/L; absolute neutrophil count [ANC] ≥ 1.5×109 cells/L without the use of&#xD;
             hematopoietic growth factors)&#xD;
&#xD;
          -  Corrected QT interval (QTc) &lt; 470 ms&#xD;
&#xD;
          -  Willing and able to participate in the trial and comply with all trial requirements&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Gastrointestinal (GI) condition that could interfere with the swallowing or absorption&#xD;
             of study medication&#xD;
&#xD;
          -  Uncontrolled or severe concurrent medical condition (including uncontrolled brain&#xD;
             metastases).&#xD;
&#xD;
          -  History of upper gastrointestinal bleeding, ulceration, or perforation within 6 months&#xD;
             prior to the first dose of protocol therapy&#xD;
&#xD;
          -  Known history of stroke or cerebrovascular accident within 6 months prior to the first&#xD;
             dose of protocol therapy.&#xD;
&#xD;
          -  Part B only: Prior therapy (including investigational agents) for pancreatic cancer&#xD;
&#xD;
          -  Chemotherapy or radiotherapy within 14 days prior to first dose of protocol therapy&#xD;
&#xD;
          -  Active treatment for a secondary malignancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hagop Youssoufian, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Verastem, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gettysburg Cancer Center</name>
      <address>
        <city>Gettysburg</city>
        <state>Pennsylvania</state>
        <zip>17325</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <study_first_submitted>January 6, 2016</study_first_submitted>
  <study_first_submitted_qc>January 7, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 11, 2016</study_first_posted>
  <last_update_submitted>July 25, 2017</last_update_submitted>
  <last_update_submitted_qc>July 25, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 27, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

